VINCI CAPITAL

beqom is a cloud-based compensation management software provider. It offers comprehensive solutions for managing total compensation, optimizing pay decisions with data-driven insights, closing pay gaps, and enhancing transparency in performance rewards. The platform caters to leading enterprises seeking to leverage talent effectively while ensuring compliance with regulatory requirements.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.

Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.

SolvAxis is a leader in the design of ERP systems for SMEs . Since 1987, they offer enterprise software and related services. Their innovative and reliable ProConcept ERP solution lets you create and manage your business processes efficiently. 15'000 users on more than 1000 sites are already working with this standard solution. They are more and more numerous every day. Relationships with their customers, prospects and partners are based on mutual trust. Thus, their employees give your project a great importance. They collaborate with you in a close and constructive way.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Omnisens SA, established in 1999 as a spin-off from the Swiss Federal Institute of Technology, specializes in optical-based real-time asset integrity monitoring solutions for the energy sector. The company develops advanced instrumentation and systems utilizing fiber optic sensing technology to enable continuous monitoring of critical infrastructures such as oil and gas pipelines, power transmission lines, and civil engineering projects. Omnisens offers a comprehensive range of solutions that include leak detection, geohazard monitoring, and performance optimization, as well as specialized monitoring techniques like Distributed Temperature and Strain Sensing, Distributed Acoustic Sensing, and Fiber Bragg Gratings. The company also provides ancillary services such as application engineering, installation, and maintenance. Headquartered in Morges, Switzerland, with an additional office in Rio de Janeiro, Brazil, Omnisens serves global markets through partnerships with system integrators and instrument resellers in North America, Latin America, Europe, the Middle East, and Asia.

Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

Datamars designs and supplies RFID-based identification and tracking solutions for animals, livestock and textiles, offering livestock management infrastructure including ear tags, readers, tissue-sampling tools, and plate meters and drafters for health monitoring and performance, enabling accurate identification and care and helping pet owners reunite with lost animals.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule drugs that act as allosteric modulators of central nervous system targets, especially G-protein coupled receptors. Based in Geneva, Switzerland, the company aims to address CNS disorders with a platform that may offer advantages over conventional orthosteric therapies. Its lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 for epilepsy and other CNS conditions, and a GABAB positive allosteric modulator for addiction. It collaborates with Janssen Pharmaceuticals to develop mGluR2 PAM compounds. Founded in 2002, Addex operates in Switzerland and Europe, pursuing discovery, development, and potential commercialization of small-molecule therapeutics for CNS disorders.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.